Death follows Kaletra overdose
Abbott has issued a Dear Healthcare Professional letter to convey the report of an accidental overdose of lopinavir/ritonavir (Kaletra) oral solution that led to the death of an infant.
Abbott has issued a Dear Healthcare Professional letter to convey the report of an accidental overdose of lopinavir/ritonavir (Kaletra) oral solution that led to the death of an infant. According to the letter, the incident occurred in an HIV-positive 44-day-old infant who received a 10-fold overdose of the oral solution and died of cardiogenic shock nine days later. Abbott reminded practitioners that pediatric dosages of Kaletra should be based on weight12 mg/kg twice daily for infants weighing 7 to 14 kg, and 10 mg/kg twice daily for children weighing 15 to 40 kg. In general, a child should receive less than 5 ml of the oral solution per dose unless he or she is also receiving certain concomitant antiretrovirals, the company warned. Kaletra oral solution contains 80 mg lopinavir and 20 mg ritonavir per ml.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
Targeted Drug Combination Reveals New Activity in Brain Tumors
December 28th 2021A combination of two targeted cancer drugs showed unprecedented, “clinically meaningful” activity in patients with highly malignant brain tumors that carried a rare genetic mutation, according to a clinical trial report by investigators from Dana-Farber Cancer Institute.
